MAP-4343

N/A

Report date: 2025/12/09 17:56:35
NME

Base Information

Drug NameMAP-4343
Drug Alias NamePregnenolone methyl ether,3-methoxy-pregnenoloneMePREGMAP-4343
ClassificationSmall molecules > Steroids
Mechanisms of ActionTubulin polymerisation promoters
TargetsMicrotubule-associated protein 2Tubulin
Therapy Area/IndicationsAutistic DisorderDepressionMarijuana Abuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMapreg
China Registration ClassN/A

Develop Information

Active CompaniesMapreg
Inactive CompaniesStanford UniversityMedical University Of South CarolinaThe Scripps Research Institute Inc
Active IndicationsDepression
Inactive IndicationsAutistic DisorderMarijuana AbuseAlcoholism

Other Information

ATC CodeN/A
Related LinksN/A